English NHS must fund value based pricing system drugs
This article was originally published in SRA
England's Department of Health has given pharmaceutical companies a little more clarity on what the new value-based pricing system might have in store when it confirmed that the National Health Service in England will have to fund drugs that are subject to the new system1. The news could mean fewer barriers than anticipated to the uptake of new medicines. Nevertheless the BioIndustry Association, representing UK biotech firms, warned that the new VBP system could make the UK a less attractive location to launch medicines.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.